FFA
REGN icon

First Foundation Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

First Foundation Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36M Buy
3,051
+2
+0.1% +$1.53K 0.09% 132
2025
Q4 		$2.35M Hold
3,049
– – 0.09% 129
2025
Q3 		$1.71M Sell
3,049
-4
-0.1% -$2.26K 0.06% 145
2025
Q2 		$1.6M Sell
3,053
-50
-2% -$27.9K 0.06% 153
2025
Q1 		$1.97M Buy
3,103
+4
+0.1% +$2.75K 0.08% 127
2024
Q4 		$2.21M Sell
3,099
-10
-0.3% -$8.39K 0.08% 117
2024
Q3 		$3.27M Hold
3,109
– – 0.12% 103
2024
Q2 		$3.27M Hold
3,109
– – 0.12% 92
2024
Q1 		$2.99M Buy
3,109
+50
+2% +$47.5K 0.12% 94
2023
Q4 		$2.69M Sell
3,059
-169
-5% -$139K 0.12% 98
2023
Q3 		$2.66M Sell
3,228
-1
-0% -$786 0.12% 102
2023
Q2 		$2.32M Sell
3,229
-138
-4% -$106K 0.1% 123
2023
Q1 		$2.77M Buy
3,367
+66
+2% +$49.8K 0.13% 108
2022
Q4 		$2.38M Buy
+3,301
New +$2.44M 0.11% 113
2021
Q4 		– Sell
-2,422
Closed -$1.47M – 462
2021
Q3 		$1.47M Sell
2,422
-377
-13% -$234K 0.05% 161
2021
Q2 		$1.56M Buy
2,799
+52
+2% +$26.3K 0.06% 164
2021
Q1 		$1.3M Buy
2,747
+1,590
+137% +$774K 0.06% 174
2020
Q4 		$559K Buy
+1,157
New +$625K 0.02% 251

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Foundation Advisors's REGN Position: Q1 2026 in Review

First Foundation Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 0.07% in Q1 2026, buying an estimated $1.53K and bringing the position to 3,051 shares worth $2.36M. The position accounts for 0.09% of the portfolio, ranked #132.

First Foundation Advisors first reported a position in REGN in Q4 2020 and has held it in 18 quarters since. The position peaked at $3.27M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • First Foundation Advisors held 3,051 shares of Regeneron Pharmaceuticals worth $2.36M as of Q1 2026.
  • First Foundation Advisors bought 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up 0.09% of First Foundation Advisors's portfolio in Q1 2026, its #132 holding.
  • First Foundation Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 18 quarters since.
  • First Foundation Advisors's Regeneron Pharmaceuticals position peaked at $3.27M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on First Foundation Advisors's 13F filing for Q1 2026, filed 4 May 2026.